CAN THE REQUIREMENT OF MEDICATIONS FOR CARDIAC SUPPORT PREDICT OUTCOME IN CANCER SURGERY PATIENTS
Not Applicable
Completed
- Conditions
- Health Condition 1: D00-D09- In situ neoplasms
- Registration Number
- CTRI/2022/09/045237
- Lead Sponsor
- Dr SNIGDHA BELLAPUKONDA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 257
Inclusion Criteria
All patients undergoing cancer surgeries and requiring Noradrenaline, Adrenaline, Vasopressin, Dopamine, Dobutamine and/or Milrinone support postoperatively from May 2022 to November 2022 will be included.
Exclusion Criteria
Patients on vasopressors or Inotropes other than mentioned. (Phenylephrine)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method